Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001213944 | SCV001385605 | uncertain significance | Jeune thoracic dystrophy; Nephronophthisis | 2023-08-28 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 943696). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt TTC21B protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals affected with TTC21B-related conditions. This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 289 of the TTC21B protein (p.Tyr289Cys). This variant is not present in population databases (gnomAD no frequency). |
Fulgent Genetics, |
RCV002491658 | SCV002785733 | uncertain significance | Asphyxiating thoracic dystrophy 4; Nephronophthisis 12 | 2022-01-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003442773 | SCV004170053 | uncertain significance | not provided | 2023-05-12 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |